X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with Dr. Reddys - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs DR. REDDYS LAB - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA DR. REDDYS LAB ABBOTT INDIA/
DR. REDDYS LAB
 
P/E (TTM) x 41.6 33.9 122.5% View Chart
P/BV x 10.4 3.3 312.2% View Chart
Dividend Yield % 0.6 0.8 79.6%  

Financials

 ABBOTT INDIA   DR. REDDYS LAB
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-16
DR. REDDYS LAB
Mar-17
ABBOTT INDIA/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs6,0153,397 177.1%   
Low Rs3,7072,560 144.8%   
Sales per share (Unadj.) Rs1,236.9856.5 144.4%  
Earnings per share (Unadj.) Rs122.278.0 156.7%  
Cash flow per share (Unadj.) Rs129.0139.9 92.2%  
Dividends per share (Unadj.) Rs35.0020.00 175.0%  
Dividend yield (eoy) %0.70.7 107.2%  
Book value per share (Unadj.) Rs521.2739.8 70.5%  
Shares outstanding (eoy) m21.25165.74 12.8%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x3.93.5 113.0%   
Avg P/E ratio x39.838.2 104.1%  
P/CF ratio (eoy) x37.721.3 177.0%  
Price / Book Value ratio x9.34.0 231.7%  
Dividend payout %28.625.7 111.7%   
Avg Mkt Cap Rs m103,296493,632 20.9%   
No. of employees `0003.022.7 13.0%   
Total wages/salary Rs m3,37031,068 10.8%   
Avg. sales/employee Rs Th8,891.86,259.0 142.1%   
Avg. wages/employee Rs Th1,140.01,369.8 83.2%   
Avg. net profit/employee Rs Th878.3569.7 154.2%   
INCOME DATA
Net Sales Rs m26,284141,961 18.5%  
Other income Rs m5041,715 29.4%   
Total revenues Rs m26,789143,676 18.6%   
Gross profit Rs m3,66524,722 14.8%  
Depreciation Rs m14410,266 1.4%   
Interest Rs m8634 1.3%   
Profit before tax Rs m4,01715,537 25.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m0349 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,4212,965 47.9%   
Profit after tax Rs m2,59612,921 20.1%  
Gross profit margin %13.917.4 80.1%  
Effective tax rate %35.419.1 185.4%   
Net profit margin %9.99.1 108.5%  
BALANCE SHEET DATA
Current assets Rs m14,44696,837 14.9%   
Current liabilities Rs m4,72584,199 5.6%   
Net working cap to sales %37.08.9 415.5%  
Current ratio x3.11.2 265.8%  
Inventory Days Days5173 70.1%  
Debtors Days Days2098 20.0%  
Net fixed assets Rs m1,113102,552 1.1%   
Share capital Rs m213829 25.6%   
"Free" reserves Rs m10,808121,792 8.9%   
Net worth Rs m11,076122,621 9.0%   
Long term debt Rs m05,449 0.0%   
Total assets Rs m16,241218,165 7.4%  
Interest coverage x497.025.5 1,948.4%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.60.7 248.7%   
Return on assets %16.06.2 258.1%  
Return on equity %23.410.5 222.4%  
Return on capital %36.312.9 281.7%  
Exports to sales %0.654.6 1.1%   
Imports to sales %12.69.4 135.2%   
Exports (fob) Rs m16277,520 0.2%   
Imports (cif) Rs m3,32213,274 25.0%   
Fx inflow Rs m26881,670 0.3%   
Fx outflow Rs m3,92726,355 14.9%   
Net fx Rs m-3,65955,315 -6.6%   
CASH FLOW
From Operations Rs m2,51421,444 11.7%  
From Investments Rs m-800-18,404 4.3%  
From Financial Activity Rs m-803-3,692 21.7%  
Net Cashflow Rs m912-1,144 -79.7%  

Share Holding

Indian Promoters % 0.0 25.5 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 5.4 146.3%  
FIIs % 0.1 35.3 0.3%  
ADR/GDR % 0.0 18.5 -  
Free float % 17.1 15.3 111.8%  
Shareholders   18,270 75,885 24.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   NOVARTIS  ASTRAZENECA PHARMA  DISHMAN PHARMA  IPCA LABS  NATCO PHARMA  

Compare ABBOTT INDIA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade Flat; Realty Sector Down 2.1%(11:30 am)

Stock markets in India are presently trading on a flattish note. Sectoral indices are trading on a mixed note with stocks in the realty sector and metal sector witnessing maximum selling pressure.

Related Views on News

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Jan 16, 2018 01:05 PM

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 5-YR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS